
Elraglusib shows significant survival benefits in metastatic pancreatic cancer combined with standard chemo.
Actuate Therapeutics presented data at ASCO 2026 showing that elraglusib, combined with gemcitabine/Abraxane or FOLFIRINOX, significantly improves median overall survival in patients with metastatic pancreatic ductal adenocarcinoma, especially those ...


